NDA 205353 · Secura
Farydak
Panobinostat Lactate · Oral
NovelAccelerated approvalPriority reviewOrphanDiscontinuedLast checked: Nov 19, 2026Latest source record: Jun 6, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Feb 23, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 23, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewMedication Guide
3 products under this application
- FARYDAK · PANOBINOSTAT LACTATE EQ 15MG BASE · CAPSULE, ORAL · Discontinued
- FARYDAK · PANOBINOSTAT LACTATE EQ 20MG BASE · CAPSULE, ORAL · Discontinued
- FARYDAK · PANOBINOSTAT LACTATE EQ 10MG BASE · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Panobinostat Lactate" as an intervention, any sponsor and status, largest first.
Abdullah KutlarAcademic, hospital or other
NCT01245179 · 18 participants (planned) · Start Nov 2010 · Primary completion Dec 31, 2026
Drug: panobinostat · For: Sickle Cell Disease
Sites: Augusta, Georgia
Abdullah KhanAcademic, hospital or other
NCT04956302 · 1 participants · Start Sep 27, 2021 · Primary completion Jun 16, 2022
Drug: Bortezomib; Daratumumab and Hyaluronidase-fihj and 2 more · For: Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
Sites: Columbus, Ohio
Muhammad FurqanAcademic, hospital or other
NCT03982134 · 0 participants · Start Sep 2019 · Primary completion May 1, 2021
Drug: PDR001; Panobinostat · For: Melanoma; Non Small Cell Lung Cancer
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Secura
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.